Qualitative and quantitative analysis of human cytotoxic T-lymphocyte responses to HIV-1 proteins. 1992

S Lamhamedi-Cherradi, and B Culmann-Penciolelli, and B Guy, and M P Kiény, and F Dreyfus, and A G Saimot, and D Sereni, and D Sicard, and J P Lévy, and E Gomard
INSERM U152, ICGM, Hôpital Cochin, Paris, France.

OBJECTIVE To study the degree of immunogenicity of each HIV-1 protein. METHODS In most viral systems, antiviral cytotoxic T-lymphocytes (CTL) from a given donor preferentially recognize only one or a small number of viral proteins. METHODS Anti-HIV CTL were generated by in vitro stimulation of peripheral blood mononuclear cells from seropositive donors and tested against multiple HIV-1 proteins or groups of proteins encoded by seven genes (env, gag, pol, nef, rev, tat and vif). Using autologous target cells infected with recombinant vaccinia viruses expressing one of the HIV-1LAI proteins, we compared the cytolytic activities obtained from bulk culture with those found in limiting dilution analysis (LDA). RESULTS Our results were noteworthy for the following reasons. (1) Each responding donor reacted simultaneously to multiple proteins; this is very unusual in other viral systems. Anti-Gag CTL were detected in most, and anti-Pol in approximately three-quarters, of the patients, together with very high amounts of the corresponding CTL precursors in LDA. CTL against Env and Nef were found in two-thirds of the patients, while Vif- and Rev-specific CTL were less frequent. Finally, Tat was seldom recognized by CTL, but its antigenicity was revealed in LDA. (2) All responding cells revealed in bulk cultures as well as in LDA were CD8+ T-cells, and their in vitro differentiation did not require the help of CD4+ T-cells. (3) Proteins from the HIV-1LAI isolate were recognized with high frequency by CTL from seropositive donors, most certainly being infected by other isolates, which suggests that relatively conserved epitopes are predominant targets of CTL. CONCLUSIONS Taken together, these results are encouraging for vaccine purposes, since anti-HIV-1 CTL stimulation is thought to be a requirement for such a vaccine.

UI MeSH Term Description Entries
D003601 Cytotoxicity Tests, Immunologic The demonstration of the cytotoxic effect on a target cell of a lymphocyte, a mediator released by a sensitized lymphocyte, an antibody, or complement. AHG-CDC Tests,Anti-Human Globulin Complement-Dependent Cytotoxicity Tests,Microcytotoxicity Tests,Anti Human Globulin Complement Dependent Cytotoxicity Tests,Anti-Human Globulin Complement-Dependent Cytotoxicity Test,Antiglobulin-Augmented Lymphocytotoxicity Test,Antiglobulin-Augmented Lymphocytotoxicity Tests,Cytotoxicity Test, Immunologic,Cytotoxicity Tests, Anti-Human Globulin Complement-Dependent,Cytotoxicity Tests, Immunological,Immunologic Cytotoxicity Test,Immunologic Cytotoxicity Tests,Lymphocytotoxicity Test, Antiglobulin-Augmented,Lymphocytotoxicity Tests, Antiglobulin-Augmented,Microcytotoxicity Test,AHG CDC Tests,AHG-CDC Test,Anti Human Globulin Complement Dependent Cytotoxicity Test,Antiglobulin Augmented Lymphocytotoxicity Test,Antiglobulin Augmented Lymphocytotoxicity Tests,Cytotoxicity Test, Immunological,Cytotoxicity Tests, Anti Human Globulin Complement Dependent,Immunological Cytotoxicity Test,Immunological Cytotoxicity Tests,Lymphocytotoxicity Test, Antiglobulin Augmented,Lymphocytotoxicity Tests, Antiglobulin Augmented
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012191 Retroviridae Proteins Proteins from the family Retroviridae. The most frequently encountered member of this family is the Rous sarcoma virus protein. Leukovirus Proteins,Retrovirus Proteins,Proteins, Leukovirus,Proteins, Retroviridae,Proteins, Retrovirus
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D016176 T-Lymphocyte Subsets A classification of T-lymphocytes, especially into helper/inducer, suppressor/effector, and cytotoxic subsets, based on structurally or functionally different populations of cells. T-Cell Subset,T-Cell Subsets,T-Lymphocyte Subset,Subset, T-Cell,Subset, T-Lymphocyte,Subsets, T-Cell,Subsets, T-Lymphocyte,T Cell Subset,T Cell Subsets,T Lymphocyte Subset,T Lymphocyte Subsets
D016915 AIDS Vaccines Vaccines or candidate vaccines containing inactivated HIV or some of its component antigens and designed to prevent or treat AIDS. Some vaccines containing antigens are recombinantly produced. AIDS Vaccine,HIV Vaccine,HIV Vaccines,Vaccine, AIDS,Vaccine, HIV
D066298 In Vitro Techniques Methods to study reactions or processes taking place in an artificial environment outside the living organism. In Vitro Test,In Vitro Testing,In Vitro Tests,In Vitro as Topic,In Vitro,In Vitro Technique,In Vitro Testings,Technique, In Vitro,Techniques, In Vitro,Test, In Vitro,Testing, In Vitro,Testings, In Vitro,Tests, In Vitro,Vitro Testing, In

Related Publications

S Lamhamedi-Cherradi, and B Culmann-Penciolelli, and B Guy, and M P Kiény, and F Dreyfus, and A G Saimot, and D Sereni, and D Sicard, and J P Lévy, and E Gomard
January 1998, Viral immunology,
S Lamhamedi-Cherradi, and B Culmann-Penciolelli, and B Guy, and M P Kiény, and F Dreyfus, and A G Saimot, and D Sereni, and D Sicard, and J P Lévy, and E Gomard
September 2002, DNA and cell biology,
S Lamhamedi-Cherradi, and B Culmann-Penciolelli, and B Guy, and M P Kiény, and F Dreyfus, and A G Saimot, and D Sereni, and D Sicard, and J P Lévy, and E Gomard
July 1999, AIDS research and human retroviruses,
S Lamhamedi-Cherradi, and B Culmann-Penciolelli, and B Guy, and M P Kiény, and F Dreyfus, and A G Saimot, and D Sereni, and D Sicard, and J P Lévy, and E Gomard
June 1996, AIDS (London, England),
S Lamhamedi-Cherradi, and B Culmann-Penciolelli, and B Guy, and M P Kiény, and F Dreyfus, and A G Saimot, and D Sereni, and D Sicard, and J P Lévy, and E Gomard
December 2009, The Journal of infectious diseases,
S Lamhamedi-Cherradi, and B Culmann-Penciolelli, and B Guy, and M P Kiény, and F Dreyfus, and A G Saimot, and D Sereni, and D Sicard, and J P Lévy, and E Gomard
February 1993, The Journal of experimental medicine,
S Lamhamedi-Cherradi, and B Culmann-Penciolelli, and B Guy, and M P Kiény, and F Dreyfus, and A G Saimot, and D Sereni, and D Sicard, and J P Lévy, and E Gomard
August 2001, AIDS research and human retroviruses,
S Lamhamedi-Cherradi, and B Culmann-Penciolelli, and B Guy, and M P Kiény, and F Dreyfus, and A G Saimot, and D Sereni, and D Sicard, and J P Lévy, and E Gomard
January 1995, Journal of immunology (Baltimore, Md. : 1950),
S Lamhamedi-Cherradi, and B Culmann-Penciolelli, and B Guy, and M P Kiény, and F Dreyfus, and A G Saimot, and D Sereni, and D Sicard, and J P Lévy, and E Gomard
February 1997, The Journal of clinical investigation,
S Lamhamedi-Cherradi, and B Culmann-Penciolelli, and B Guy, and M P Kiény, and F Dreyfus, and A G Saimot, and D Sereni, and D Sicard, and J P Lévy, and E Gomard
January 1994, Cellular and molecular biology (Noisy-le-Grand, France),
Copied contents to your clipboard!